DABIGATRAN ETEXILATE
Manufacturer: AvKARE
Score: 148.0
Dabigatran etexilate is a direct thrombin inhibitor used to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and prevent recurrence of these conditions. The drug has several key clinical findings and indications, including a reduced risk of stroke and systemic embolism, and is generally well-tolerated but can cause bleeding and other adverse reactions. Important safety information includes warnings about premature discontinuation, spinal/epidural hematoma, and bleeding risks, as well as contraindications for patients with active pathological bleeding, serious hypersensitivity reactions, or mechanical prosthetic heart valves. The main dosing recommendations vary depending on the condition being treated and patient factors such as renal function, with dose adjustments needed for patients with renal impairment. Special population considerations include use during pregnancy, nursing, pediatric use, and geriatric use, with careful monitoring and dose adjustment recommended as needed.
Premature discontinuation of dabigatran increases the risk of thrombotic events, and spinal/epidural hematoma can occur in patients treated with dabigatran who are receiving neuraxial anesthesia or undergoing spinal puncture
Dose adjustments needed for patients with renal impairment, with reduced doses recommended for patients with severe renal impairment
150 mg orally, twice daily
Not established
150 mg orally, twice daily after 5-10 days of parenteral anticoagulation
Not established
110 mg orally, first day, then 220 mg once daily
Not established